RBC Capita Affirms XOMA (XOMA) at 'Sector Perform'; Gevokizumab Sale Could Bring in More non-Dilutive Cash

March 10, 2016 7:41 AM

RBC Capita affirms XOMA Corporation (Nasdaq: XOMA) with a Sector Perform rating and $2 price target following Q4 results and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found